Treatment of relapsed/refractory (R/R) B-cell malignancies by chimeric antigen receptor T cells cultured from 50-100 mL peripheral blood in 7-10 days.

被引：0
|
作者：
Han, Lu
Zhou, Jian
Zhou, Ke-Shu
Zhao, Ling-Di
Zhu, Xing-Hu
Yin, Qing-Song
机构：
[1] Washington Univ Sch Med, Div Publ Hlth Sci, Dept Surg, St Louis, MO USA
[2] Washington Univ St Louis, St Louis, MO USA
[3] Siteman Canc Ctr, St Louis, MO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.7034
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7034
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Radiotherapy Combined Chimeric Antigen Receptor T-Cells Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma(R/R DLBCL)
    Zhou, Lili
    Liu, Yifan
    Ye, Shiguang
    Li, Ping
    Li, Shaoguang
    Liang, Aibin
    BLOOD, 2023, 142
  • [2] Durable Remission Following "Off-the-Shelf" Chimeric Antigen Receptor (CAR) T-Cells in Patients with Relapse/Refractory (R/R) B-Cell Malignancies
    Curran, Kevin J.
    Sauter, Craig S.
    Kernan, Nancy A.
    Prockop, Susan E.
    Boulad, Farid
    Perales, Miguel
    Giralt, Sergio A.
    Riviere, Isabelle
    Wang, Xiuyan
    Boelens, Jaap-Jan
    Sadelain, Michel
    Brentjens, Renier
    O'Reilly, Richard J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S89 - S89
  • [3] Chimeric antigen receptor T-cell treatment patterns in relapsed or refractory large B-cell lymphoma
    Seyedin, Roxanna
    Snider, Julia T.
    Rajagopalan, Krithika
    Wade, Sally W.
    Gergis, Usama
    FUTURE ONCOLOGY, 2023, 19 (22) : 1535 - 1547
  • [4] Factors Associated with Costs in Chimeric Antigen Receptor T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies
    Zhu, Feng
    Wei, Guoqing
    Zhang, Mingming
    Zhao, Houli
    Wu, Wenjun
    Yang, Luxin
    Hu, Yongxian
    Huang, He
    CELL TRANSPLANTATION, 2020, 29
  • [5] Treatment of Chemotherapy-Refractory B-Cell Malignancies with Anti-CD19 Chimeric Antigen Receptor T Cells
    Kochenderfer, James N.
    Kassim, Sadik H.
    Somerville, Robert
    Dudley, Mark E.
    Carpenter, Robert O.
    Lu, Lily
    Feldman, Steven A.
    Morton, Kathleen E.
    Toomey, Mary Ann
    Rosenberg, Steven A.
    MOLECULAR THERAPY, 2014, 22 : S295 - S295
  • [6] Incidence and Risk Factors Associated with Infection after Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory B-cell Malignancies
    Zhu, Feng
    Wei, Guoqing
    Liu, Yandan
    Zhou, Houli
    Wu, Wenjun
    Yang, Luxin
    Huang, He
    Hu, Yongxian
    CELL TRANSPLANTATION, 2021, 30
  • [7] Incidence and Risk Factors Associated with Infection after Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory B-Cell Malignancies
    Zhu, Feng
    Hu, Yongxian
    Wei Guoqing
    Huang, He
    Wu, Wenjun
    BLOOD, 2019, 134
  • [8] Allogeneic chimeric antigen receptor T cells for children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
    Locatelli, Franco
    del Bufalo, Francesca
    Quintarelli, Concetta
    HAEMATOLOGICA, 2024, 109 (06) : 1689 - 1699
  • [9] The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B-cell malignancies
    Brillembourg, Helena
    Martinez-Cibrian, Nuria
    Bachiller, Mireia
    Alserawan, Leticia
    Ortiz-Maldonado, Valentin
    Guedan, Sonia
    Delgado, Julio
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (05) : 1649 - 1659
  • [10] Efficacy and Safety of Chimeric Antigen Receptor T Cells Therapy Combined with Zanubrutinib in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Wang, Langqi
    Yang, Jilong
    Jin, Bo
    Wang, Bo
    Zhou, Lijuan
    Zhuo, Yaqi
    Chen, Huifang
    Chang, Lung-Ji
    Tu, Sanfang
    Li, Yuhua
    BLOOD, 2023, 142
12345